Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug?

Arthritis and Rheumatology

Volumn 69, Issue 7, 2017, Pages 1346-1349

  Bootsma, Hendrika ^a   Kroese, Frans G M ^a   Vissink, Arjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; EDITORIAL; HUMAN; HYPERACTIVITY; PRIORITY JOURNAL; SJOEGREN SYNDROME; COST BENEFIT ANALYSIS; FATIGUE; XEROSTOMIA;

COST-BENEFIT ANALYSIS; FATIGUE; HUMANS; RITUXIMAB; SJOGREN'S SYNDROME; XEROSTOMIA;

EID: 85020307337     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40095     Document Type: Editorial

References (25)

1. Kroese FG, Abdulahad WH, Haacke E, Bos NA, Vissink A, Bootsma H. B-cell hyperactivity in primary Sjögren's syndrome. Expert Rev Clin Immunol 2014;10:483–99.
2. Van Nimwegen JF, Moerman RV, Sillevis Smitt N, Brouwer E, Bootsma H, Vissink A. Safety of treatments for primary Sjögren's syndrome. Expert Opin Drug Saf 2016;15:513–24.
3. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014;160:233–42.
4. Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren's syndrome. Arthritis Rheumatol 2017;69:1440–50.
5. Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, et al. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology (Oxford) 2015;54:1699–708.
6. Delli K, Haacke EA, Kroese FG, Pollard RP, Ihrler S, van der Vegt B, et al. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Ann Rheum Dis 2016;75:1933–8.
7. Vissink A, Bootsma H. Connective tissue diseases: refining the classification criteria for primary Sjögren syndrome. Nat Rev Rheumatol 2017;13:10–2.
8. Lendrem D, Howard Tripp N, Mariette X, Johnsen SJ, Tarn J, Hackett K, et al. Rethinking primary Sjögren's syndrome: stratification by clinical phenotypes to improve understanding of disease pathogenesis, trial design, clinical management and prospective health gains? [abstract]. Arthritis Rheumatol 2016;68 Suppl 10. URL: http://acrabstracts.org/abstract/rethinking-primary-sjogrens-syndrome-stratification-by-clinical-phenotypes-to-improve-understanding-of-disease-pathogenesis-trial-design-clinical-management-and-prospective-health-gains/.
9. Verstappen GM, Kroese FG, Meiners PM, Corneth OB, Huitema MG, Haacke EA, et al. B-cell depletion therapy normalizes circulating follicular Th cells in primary Sjögren syndrome. J Rheumatol 2017;44:49–58.
10. De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. Rheumatology (Oxford) 2015;54:2249–56.
11. Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, et al. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 2014;73:1393–6.
12. Pijpe J, Meijer JM, Bootsma H, van der Wal JE, Spijkervet FK, Kallenberg CG, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum 2009;60:3251–6.
13. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740–50.
14. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960–8.
15. Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 2013;15:R172.
16. St.Clair EW, Levesque MC, Prak ET, Vivino FB, Alappatt CJ, Spychala ME, et al. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum 2013;65:1097–106.
17. Cornec D, Jousse-Joulin S, Costa S, Marhadour T, Marcorelles P, Berthelot JM, et al. High-grade salivary-gland involvement, assessed by histology or ultrasonography, is associated with a poor response to a single rituximab course in primary Sjögren's syndrome: data from the TEARS randomized trial. PLoS One 2016b;11:e0162787.
18. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al, on behalf of the EULAR Sjögren's Task Force. EULAR Sjögren's Syndrome Disease Activity Index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010;69:1103–9.
19. Seror R, Meiners P, Baron G, Bootsma H, Bowman SJ, Vitali C, et al, EULAR Sjögren Task Force. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Ann Rheum Dis 2016;75:1945–50.
20. Moerman RV, Arends S, Meiners PM, Brouwer E, Spijkervet FK, Kroese FG, et al. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis 2014;73:472–4.
21. Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR Primary Sjögren's Syndrome Disease Activity (ESSDAI) and Patient-Reported Indexes (ESSPRI). Ann Rheum Dis 2016;75:382–9.
22. Pollard RP, Pijpe J, Bootsma H, Spijkervet FK, Kluin PM, Roodenburg JL, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome: a retrospective clinical study. J Rheumatol 2011;38:2198–208.
23. Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. Ann Rheum Dis 2011;70:968–72.
24. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al, and the International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 2017;69:35–45.
25. Oni C, Mitchell S, James K, Ng WF, Griffiths B, Hindmarsh V, et al. Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. Rheumatology (Oxford) 2016;55:544–52.